Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 4

INFINITY PHARMACEUTICALS, INC.

Form 4

September 11, 2012

FORM	FORM 4 UNITED STATES SECUDITIES AND EXCHANCE COMMISSION						OMB APPROVAL			
	AND EXCH 1, D.C. 2054	ND EXCHANGE COMMISSION D.C. 20549				3235-0287				
Check t if no lor subject Section	ger o STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF								Expires: January 31, 2005 Estimated average burden hours per	
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Find pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Beacon Co	Symbol					5. Relationship of Reporting Person(s) to Issuer				
						(Check all applicable)				
(Last)	(Month)	3. Date of Earliest Transaction (Month/Day/Year)				DirectorX 10% Owner Officer (give title below) Other (specify below)				
	C/O OGIER HOUSE, THE 09/07/2012 ESPLANADE, ST. HELIER									
		Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
JERSEY CHANNEL ISLANDS JE4 9WG — Form filed by More than One Reporting Person										
(City)	(State)	(Zip) Tal	ble I - Non-	Derivative Sec	uritie	s Acqui	red, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Date, if Transaction Disposed of (D) Code (Instr. 3, 4 and 5) y/Year) (Instr. 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock							3,000,000	D		
Common Stock	09/07/2012		P	5,416,565	A	\$ 14.5	5,416,565	I	By Purdue Pharma L.P. (1)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form SEC 1474 (9-02)

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amor Underlying Secur (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am Nui Sha
Stock Purchase Warrants (right to buy)	\$ 20 (2)	01/07/2009		H(2)	500,000	01/07/2009	07/01/2010(2)	Common Stock	50
Stock Purchase Warrants (right to buy)	\$ 30 (2)	01/07/2009		H(2)	1,000,000	01/07/2009	07/01/2011(2)	Common Stock	1,0
Stock Purchase Warrants (right to buy)	\$ 40 (2)	01/07/2009		H(2)	1,500,000	01/07/2009	07/02/2012(2)	Common Stock	1,:

Reporting Owners

Reporting Owner Name / Address	Kelationships				
	Director	10% Owner	Officer	Other	
Beacon Co					
C/O OGIER HOUSE, THE ESPLANADE		X			
ST. HELIER		Λ			
JERSEY CHANNEL ISLANDS JE4 9WG					

Signatures

/s/ Anthony M. Roncalli, as Assistant Secretary of Beacon
Company

09/07/2012

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 4

- These securities were purchased by Purdue Pharma L.P. pursuant to the Securities Purchase Agreement between the Issuer, Purdue

 Pharma L.P., Rosebay Medical Company L.P. and the Reporting Person, dated July 17, 2012 (the "Securities Purchase Agreement"). The Reporting Person and Rosebay Medical Company L.P. are the ultimate parents of Purdue Pharma L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.
- (2) These warrants expired and were not exercised by the holder.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.